跳至主要内容
临床试验/NCT00002029
NCT00002029已完成不适用

Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent

Abbott2 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
试验地点
2

研究概览

简要总结

To compare two lipid emulsions in the long-term parenteral alimentation of patients with AIDS in relation to: Clinical effectiveness. Effect on immunologic function. Effect on HIV load as measured by p24 antigen levels. Effect on relative HIV infectivity.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Concurrent Medication:
  • •Zidovudine (AZT).
  • •All drugs used for the standard treatment of opportunistic infections.
  • •Other drugs used for the treatment of other AIDS conditions if they have been started more than 3 months prior to study entry.
  • •Patients must have:
  • •Diagnosis of AIDS.
  • •Weight loss of > 10 percent premorbid body weight.
  • •Presenting diagnosis of either opportunistic infection or Kaposi's sarcoma.
  • •Require home total parenteral nutrition (TPN) for a period of approximately 3 months.
  • •Life expectancy = or > 90 days.
  • •Prior Medication:
  • •Zidovudine (AZT).

排除标准

  • •Co-existing Condition:
  • •Patients with the following conditions or symptoms are excluded:
  • •Life expectancy < 90 days.
  • •Biliary stasis.
  • •History of drug abuse.
  • •Patients with the following are excluded:
  • •Life expectancy < 90 days.
  • •Biliary stasis.
  • •History of drug abuse.
  • •Prior Medication:
  • •Excluded within 3 months of study entry:
  • •Immunomodulators.
  • •Experimental antiviral DT. History of drug abuse.

研究者

发起方
Abbott
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验